ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    esostrate
Previous Study | Return to List | Next Study

Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy (Esostrate)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02551458
Recruitment Status : Recruiting
First Posted : September 16, 2015
Last Update Posted : September 16, 2015
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire Dijon

Brief Summary:

Step 1: Inclusion of eligible patients to carry out a translational search for prognostic and predictive markers of Complete Clinical Response and Pathologic Complete Response (using blood samples and diagnostic biopsies) and to collect data on radiochemotherapy and its toxicity.

The trial will evaluate strategies after neoadjuvant treatment and not RCT protocols. The RCT will thus be chosen by the investigator from published effective schemes in a pre-operative setting or in patients not undergoing surgery.

Evaluation of the response 5 to 6 weeks after the RCT.

Step 2: Randomisation in patients with a complete clinical response:

Arm A: Systematic surgery Arm B: Surveillance and rescue surgery in cases with resectable loco-regional recurrence

Patients not eligible for randomisation will have the possibility to participate in a specific study (information can be obtained from the SAKK group (Switzerland Group Clinical Research on Cancer)).


Condition or disease Intervention/treatment Phase
Epidermoid Carcinoma or Adenocarcinoma of the Thoracic Oesophagus or Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II) Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 Other: Systematic surgery Other: Surveillance and rescue surgery in cases of resectable loco-regional recurrence Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Official Title: SYSTEMATIC SURGERY VERSUS SURVEILLANCE AND RESCUE SURGERY IN OPERABLE CANCER OF THE OESOPHAGUS WITH A COMPLETE CLINICAL RESPONSE TO RADIOCHEMOTHERAPY
Estimated Primary Completion Date : March 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A: Systematic surgery Other: Systematic surgery
Experimental: Arm B: Surveillance and rescue surgery in cases of resectable Other: Surveillance and rescue surgery in cases of resectable loco-regional recurrence



Primary Outcome Measures :
  1. Proportion of surviving patients [ Time Frame: 1 year after randomisation ]
  2. Disease-free survival [ Time Frame: Up to 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Epidermoid carcinoma (EC) or adenocarcinoma of the thoracic oesophagus or adenocarcinoma of the oesogastric junction (Siewert type I or II) proven histologically
  • Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 after a full investigation
  • Patient considered operable with a curative intent and scheduled to undergo first-line radiochemotherapy in a multidisciplinary meeting
  • Age ≥ 18 years < 75 years
  • Patient with national health insurance cover and who has provided written informed consent for the clinical and biological studies.

Exclusion Criteria:

  • Cancer of the cervical oesophagus (15 to 19 cm from the dental arches)
  • Weight loss > 15% at the recruitment with no improvement after nutritional support
  • Serious comorbidity threatening survival in the short term
  • Contra-indication for radiochemotherapy
  • Other uncured malignant disease in the 5 previous years (except for in situ cervical carcinoma and treated non-melanotic skin cancers)
  • Absence of effective contraception in patients (men or women) able to procreate, pregnant or breast-feeding women
  • Impossibility to follow the trial
  • Legal disqualification (patients in custody or under guardianship)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02551458


Contacts
Contact: Laurent BEDENNE 3 80 38 13 14 ext +33 laurent.bedenne@u-bourgogne.fr

Locations
France
CHU Amiens Recruiting
Amiens, France, 80054
Contact: Jean-Marc REGIMBAUD         
Centre d'oncologie et de radiothérapie du Pays Basque Recruiting
Bayonne, France, 64100
Contact: Stéphane REMY         
CH de la Côte Basque Recruiting
Bayonne, France, 64109
Contact: Franck AUDEMAR         
Boulogne Sur Mer Recruiting
Boulogne-sur-mer, France, 62200
Contact: Vincent BOURGEOIS         
Infirmerie protestante de Lyon Recruiting
Caluire et Cuire, France, 69300
Contact: Johannes HATWIG         
Hôpitaux civils de Colmar Recruiting
Colmar, France, 68024
Contact: Gilles BREYSACHER         
CHU de DIJON Recruiting
Dijon, France, 21079
Contact: Laurent BEDENNE         
Hôpital Michallon (GRENOBLE) Recruiting
La Tronche, France, 38700
Contact: Jacques BALOSSO         
Centre Oscar Lambret Recruiting
Lille, France, 59000
Contact: Antoine ADENIS         
Hôpital Claude Huriez Recruiting
Lille, France, 59000
Contact: Antoine ADENIS         
Clinique Chenieux Recruiting
Limoges, France, 87039
Contact: Xavier ZASADNY         
CHU de Limoges Recruiting
Limoges, France, 87042
Contact: Sandrine LAVAU-DENES         
CH Saint Joseph Saint Luc Recruiting
Lyon, France, 69007
Contact: Denis PERE VERGE         
Hôpital privé Jean Mermoz Recruiting
Lyon, France, 69008
Contact: Gérard LLEDO         
Institut Mutualiste MONTSOURIS Recruiting
Paris, France, 75014
Contact: Christophe LOUVET         
Centre Hospitalier Annecy Genevois Recruiting
Pringy, France, 74374
Contact: Mathieu BACONNIER         
CHP Saint Grégoire Recruiting
Saint Gregoire, France, 35760
Contact: Laurent MUGLIANICO         
Institut Gustave Roussy Recruiting
Villejuif, France, 94800
Contact: Eric DEUTSCH         
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon

Responsible Party: Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier: NCT02551458     History of Changes
Other Study ID Numbers: Bedenne PHRC N 2013
First Posted: September 16, 2015    Key Record Dates
Last Update Posted: September 16, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell